Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;35(5):1480-1484.
doi: 10.1038/s41375-021-01171-y. Epub 2021 Mar 3.

Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

Genki Yamato  1   2 , Takao Deguchi  3 , Kiminori Terui  4 , Tsutomu Toki  4 , Tomoyuki Watanabe  5 , Takahiro Imaizumi  6 , Asahito Hama  7 , Shotaro Iwamoto  8 , Daisuke Hasegawa  9 , Takahiro Ueda  10 , Tomoko Yokosuka  11 , Shiro Tanaka  12 , Ryu Yanagisawa  13 , Katsuyoshi Koh  14 , Akiko M Saito  15 , Keizo Horibe  15 , Yasuhide Hayashi  1   16 , Souichi Adachi  17 , Shuki Mizutani  18 , Takashi Taga  19 , Etsuro Ito  4 , Kenichiro Watanabe  20 , Hideki Muramatsu  21
Affiliations

Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome

Genki Yamato et al. Leukemia. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Outcomes of 167 patients with TAM and FCM-MRD analysis to predict leukemia development.
Kaplan–Meier curves of overall survival (A) and event-free survival (B). Cumulative incidence rates of early death (C) and leukemia development (D). Cumulative incidence rates of leukemia development between TAM patients with and without FCM-MRD positivity at 1 month (positive, n = 107; negative, n = 26; CIR [95% CI] = 25.2% [17.3–33.9%] vs 3.8% [0.3–16.8%], P = 0.022) (E) and 3 months (positive, n = 20; negative, n = 84; CIR [95% CI], 45.0% [22.3–65.4%] vs. 16.0% [9.0–24.8%], P = 0.002) (F).
Fig. 2
Fig. 2. LDAC intervention is an indispensable therapy aimed at reducing the early death rate.
A Subgroup analysis in patients with a high WBC count (≥100 × 109 cells/L). The cumulative incidence rate of early death in 36 patients with a high WBC count indicated that LDAC therapy significantly improved survival (CIR [95% CI], 31% [13–50%] vs. 62% [29–83%], P = 0.017). B LDAC intervention was adversely associated with the early death rate. In the meta-analysis of large cohorts including this study and five other published studies, a higher proportion of patients receiving the LDAC intervention was significantly associated with a lower early death rate using the Cochran-Armitage test for trend.
See this image and copyright information in PMC

References

    1. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005;217:126–34. doi: 10.1055/s-2005-836510. - DOI - PubMed
    1. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31. doi: 10.1182/blood-2007-01-069542. - DOI - PubMed
    1. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752–9. doi: 10.1182/blood-2011-04-350017. - DOI - PMC - PubMed
    1. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111:2991–8. doi: 10.1182/blood-2007-10-118810. - DOI - PMC - PubMed
    1. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, et al. Children’s Oncology Group (COG). A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13. doi: 10.1182/blood-2005-06-2448. - DOI - PubMed

Publication types

Supplementary concepts